Noemí Puig, MD, PhD, of the University Hospital Salamanca, Salamanca, Spain, reports results from the GEM-CLARIDEX study (NCT02575144), evaluating lenalidomide and dexamethasone plus or minus clarithromycin in untreated, newly-diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).